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Iron deﬁciencyArsenic is a double-edge sword. On the one hand it is powerful carcinogen and on the other it is used ther-
apeutically to treat acute promyelocytic leukemia. Here we report that arsenic activates the iron responsive
transcription factor, Aft1, as a consequence of a defective high-afﬁnity iron uptake mediated by Fet3 and Ftr1,
whose mRNAs are drastically decreased upon arsenic exposure. Moreover, arsenic causes the internalization
and degradation of Fet3. Most importantly, fet3ftr1 mutant exhibits increased arsenic resistance and de-
creased arsenic accumulation over the wild-type suggesting that Fet3 plays a role in arsenic toxicity. Finally
we provide data suggesting that arsenic also disrupts iron uptake in mammals and the link between Fet3, ar-
senic and iron, can be relevant to clinical applications.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Arsenic (As), the 20th most abundant element in the earth's crust
is a highly toxic metalloid with respect to human health [1]. Although
often synonymous to a poison, it is one of the oldest drugs in history
of mankind, ﬁrst used to treat cutaneous ulcers, later periodic fever
and malaria, and currently as treatment for acute promyelocytic leu-
kemia (PML) [2]. Due to its paradoxical biological effects, As has
been the object of intense scrutiny, with regards to its cellular me-
tabolism and molecular biological impact. However to date, these
studies have never established a link between As and iron (Fe)
homeostasis.
Cells require Fe for a wide array of metabolic functions, which in-
clude oxygen transport, cellular respiration, lipidmetabolism, gene reg-
ulation and DNA replication and repair, yet Fe is toxic when present in
excess [3]. Saccharomyces cerevisiae expresses three distinct transport
pathways for Fe, two reductive systems and a non-reductive one. The
reductive pathways consist of low- and high-afﬁnity uptake systems op-
erated by Fet4, and by a protein complex composed of the multicopper
ferroxidase Fet3 and the permease Ftr1, respectively. The Fet3–Ftr1
complex is speciﬁc for Fe and is regulated both transcriptionally and
post-transcriptionally by Fe [4–6]. The non-reductive Fe uptake pathway
is mediated by the ARN family (Arn1-4) of membrane permeases that
transport siderophore-ferric iron complexes [7]. In S. cerevisiae, these
Fe uptake systems are all induced under Fe scarce conditions by the+351 214469625.
ousada).
rights reserved.Aft1 transcription factor and its homologue Aft2, as part of the Fe
regulon [8].
We have here conducted a genome-wide mRNA proﬁling of the
S. cerevisiae response to arsenate (AsV), which revealed a potent induc-
tion of the Fe gene regulon. However, neither FET3 nor FTR1 appeared
induced by this treatment. Strikingly, AsV caused the immediate inter-
nalization of Fet3 in the endoplasmic reticulum (ER) and the apparent
lack of FET3 transcriptional induction was in fact the consequence of
the degradation of itsmRNAby themajor pathway formRNAdecayme-
diated by the 5′-3′ exonuclease Xrn1. Moreover, increased AsV toler-
ance in strains with null mutations of either FET3 or FTR1, together
with a decrease AsV cellular uptake in these mutant strains, indicate a
role of Fet3 and Ftr1 in mediating AsV cellular uptake and toxicity.
Taken together this work provides a molecular connection between
As toxicity and Fe homeostasis, which should be relevant to further
understand the toxic and therapeutic effects of As at the molecular
level.2. Materials and methods
2.1. Yeast strains and growth conditions
The plasmids and yeast strains used in this study are listed in supple-
mentary Table S3. Spot assays were carried out by spotting 5 μl of early
exponential phase cultures (A600=0.4) sequentially diluted (approxi-
mately 5×103 to 10 cells) in medium containing 2 mM Na2HAsO4
(AsV), 100 μM Fe2(SO4)3 (Fe3+) or 50 μM BPS. Growth was recorded
after incubation for 2 days at 30 °C.
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Wild-type (WT) cells were grown in triplicate in media containing
2 mM of AsV for 1 hour, and RNAwas extracted, labeled, and hybridized
to Affymetrix Yeast Genome S98 arrays. (For further information visit the
Duke Microarray Core Facility at http://www.genome.duke.edu/cores/
microarray/). All data were analyzed using both Partek® Genomics
SuiteTM and dChip softwares. Data have been deposited in the NCBI
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) and are
accessible through GEO Series accession number GSE33427.
2.3. RNA blot analysis
Total yeast RNA was isolated from cells untreated or treated
with either 2 mM of AsV, 100 μM of Fe2(SO4)3 (Fe3+), 100 μM of
BPS or 400 μM H2O2. PCR-ampliﬁed fragments were radiolabeled
with 32P-dCTP to be used as probes. U3, a small nuclear RNA
(SNR17A), was used as loading control.
2.4. Real-time PCR analysis
RNA was extracted from early log-phase cultures that were either
untreated or exposed during 60 min to 2 mM AsV. DNA was removed
by on-column DNAse I digestion (RNase-Free DNase Set; Qiagen).
Total RNA (1ìg) was reverse transcribed with Transcriptor Reverse
Transcriptase (Roche Diagnostics). qPCR reactions were performed
in the LightCycler 480 Instrument (Roche), using LightCycler 480
Green I Master (Roche) and the oligonucleotides are listed in supple-
mentary Table S4. Actin (ACT1) was used as a reference gene. All as-
says were made in triplicate.
2.5. β-Galactosidase assay
WT cells and the isogenic aft1 mutant were transformed with a
β-galactosidase reporter plasmid containing the promoter sequence
of CTH2 previously described [9], pCM64-CTH2-FeRE-CYC1-LacZ. WT
was also co-transformed with the plasmids pEG202LexA-AFT1 and
pSH18-34. β-Galactosidase was measured in triplicate following the
degradation of the colorimetric substrate ONPG (o-nitrophenyl-b-
D-galactopyraniside) at A420 and normalized against total protein
concentration.
2.6. Measurement of total iron and arsenic
Strains were grown in YPD media with 1 mM of AsV for 2 or
4 hours, collected by centrifugation and washed with 10 mM EDTA
and metal-free water. The total Fe and As were measured by induc-
tively coupled plasma (ICP) atomic emission spectroscopy.
2.7. Protein analysis
Protein extracts were generated from cell cultures using cell lysis
buffer supplemented with protease inhibitors (Roche). Proteinwas re-
solved by SDS–PAGE, and immunoblotted with Anti-HA and Anti-cMyc
(Roche) Anti-TAP-tag (Life Technologies). Anti-Pgk1 (Life Technologies)
was used as loading control.
2.8. Fluorescence microscopy
Microscopy experiments were carried out on live cultures using
LEICADMRA2Microscope coupledwith a CoolSNAPTMHQPhotometrics
camera (Roper Scientiﬁc). The analysis of ﬂuorescence intensity was
done using theMetaMorph software package (MDS Analytical Technol-
ogies). Overnight liquid cultures expressing Aft1-GFP, Fet3-GFP or
Sec63-GFP were re-inoculated to an optical density A600=0.1 in YPD
medium containing 1 mM of AsV, 100 μMof BPS (Bathophenanthrolinedisulfonate), 100 μM BSC (Bathocuproine disulphonate) or 10 μM
Cu2SO4. After washing with phosphate-buffered saline (PBS) cells
were resuspended in DABCO solution and visualized.
2.9. Cells and media
Mousse embryonic ﬁbroblasts (MEF) cells and HeLa cells were Fe
loaded by addition of Ferric ammonium citrate (Fe3+, 100 μM) and
Fe depleted by addition of desferroxamine 5 μM and treated with ar-
senic trioxide (AsIII, 5 μM) for 24 hours. To extract protein, cells were
solubilized in 1.0% of Triton X-100, 150 mM NaCl, 10 mM EDTA, and
10 mM Tris (pH7.4) with a protease inhibitor cocktail (Roche). Pro-
tein was resolved by 12% SDS–PAGE and transferred to a nitrocellu-
lose membrane (GE Healthcare). Ferritin levels were detected using
Mouse Anti-Ferritin (Abcam), Ccs1 levels using Rabbit Anti-Ccs1
(Santa Cruz Biotechnology, Inc), and Rat Anti-Tubulin (Novus Biolog-
icals) was used as a loading control.
3. Results
3.1. The Saccharomyces cerevisiae genome-wide response to arsenic
exposure
In S. cerevisiae, resistance to AsV has been ascribed to Yap1 and
Yap8, two AP-1 like transcription factors that regulate the expression
of genes involved in redox homeostasis and As detoxiﬁcation process-
es, respectively [10]. To identify novel As tolerance pathways, we an-
alyzed the genome-wide mRNAs proﬁle of yeast cells exposed to AsV.
Fig. 1 summarizes the results of these experiments (see data deposit
in http://www.ncbi.nlm.nih.gov/geo/). In total, 1608 genes had their
expression signiﬁcantly altered upon AsV exposure. Classiﬁcation of
these genes by Gene Ontology showed that they belonged to many
functional categories, including the response to metals and oxidative
stress, cell cycle, mRNA processing, mitochondrial related-processes,
transcriptional and translational activity, transporter activity, endo-
plasmic reticulum related-processes, protein folding, among others
(Fig. 1A). Many of these genes have already been shown to respond
to As [11,12]. However expression of genes responsive to metals,
such as, zinc, iron (Fe) and copper (Supplementary Fig. S1A) has
never been shown to be altered by As. Within the cellular Fe homeo-
stasis category, 82 genes showed changes of at least 1.2-fold in their
expression levels in response to AsV stress (Fig. 1B and Supplementa-
ry Table S1). Among these, many of the genes of the Aft1/2 regulon
[13–15] were present, such as CTH2, the ARN family genes and FIT3
that encode cell wall mannoproteins involved in siderophore-Fe3+ up-
take (Fig. 1C and Supplementary Table S2). Surprisingly, despite a large
induction of the Aft1/2 regulon, FET3 and FTR1 mRNA levels appeared
signiﬁcantly decreased upon AsV exposure (Fig. 1C and Supplementary
Table S1). Moreover the samewas observed for FET3mRNA levels upon
arsenite (AsIII) exposure (Supplementary Fig. S1B).
3.2. Arsenic activates Aft1 and causes Fe scarcity
Except for FET3 and FTR1, the mRNA proﬁling analysis indicated
that AsV exposure mimics the genomic response to Fe deﬁciency.
Yeast cells respond to Fe deprivation by the Aft1/2-dependent tran-
scriptional activation of the Fe regulon that encodes proteins involved
in Fe uptake, trafﬁcking and utilization [16]. Aft1 is controlled at the
level of its nucleocytoplasmic distribution. To conﬁrm that AsV can
activate Aft1/2, we monitored by ﬂuorescence microscopy the kinet-
ics cellular localization of an Aft1-GFP fusion in cells exposed to AsV
(Fig. 2A). After 40 minutes of exposure to AsV, Aft1-GFP ﬂuorescence
was indeed shifted from a diffuse to a nuclear pattern, similar to what
is seen in cells treated with the iron chelator BPS. Subcellular localiza-
tion of a Myc-Aft1 fusion by cellular fractionation similarly showed
that in AsV-treated lysates, Aft1 was almost exclusively seen in the
Fig. 1.Genome-wide response of Saccharomyces cerevisiae upon arsenate exposure. (A) Representation of the results from triplicate Affymetrix DNAmicroarray studies showing the Gene
Ontology of the main categories with at least 50% of the mRNAs changed. (B) Representation of the total number of mRNAs corresponding to Fe-dependent processes. (C) Microarray
validation by RT-PCR.
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was evenly distributed between the cytosolic and nuclear fraction
(Fig. 2B). AsV also induced the expression of the Aft1-dependent
gene CTH2 to levels similar to those triggered by BPS, as monitored
using a promoter-LacZ fusion (Fig. 2C). In the aft1 mutant, AsV-
induced CTH2 expression was abolished. To question the physiologi-
cal link between As and the Aft1/2 regulon, we next evaluated As tol-
erance of aft1 and aft2 single mutants by growth in the presence of
AsV (2 mM). The aft1 mutant was unable to grow under this condi-
tion, while the aft2 mutant displayed a normal growth (Fig. 2D). In-
terestingly AsV-dependent growth inhibition of aft1 mutant could
be totally reversed by addition of Fe3+ (Fig. 2D), which indicates
that AsV not only activates the Aft1/2-dependent Fe-deprivation re-
sponse, but also causes Fe scarcity.
3.3. Arsenic triggers degradation of FET3mRNAby the 5′-3′ exonuclease Xrn1
As shown above, AsV potently induced the genes of the Fe regulon,
with the notable exception of FET3 and FTR1 that were paradoxically
down-regulated (Fig. 1C, and Supplementary Table S2). Fet3 is the
multicopper oxidase that oxidizes ferrous (Fe2+) to ferric iron (Fe3+),
for subsequent cellular uptake by the transmembrane permease Ftr1[17,18]. Aft1 activates the Cth1 and Cth2 mRNA-binding proteins that
promote decay of the Fe binding proteins-encoded mRNAs containing
AREs in their 3′ UTR [3]. However, similar to AsV-treated WT cells, the
FET3 mRNAs remained undetectable in a cth2 mutant exposed to AsV
(Fig. 3A), consistent with the notion that FET3 does not carry any
Cth1/2 AREs in its 3′ UTR.
A major route for mRNA degradation in eukaryotic cells begins with
poly-A deadenylation by Ccr4, followed by decapping by Dcp1/2, and
5′-3′ exonucleotidic decay by Xrn1 [19,20]. To test the possible role of
this pathway in mediating AsV-dependent FET3 mRNA decay we used
ccr4 and xrn1 mutants. Importantly, the xrn1 mutant treated with AsV
expressed FET3 at levels similar to those of untreated wild-type cells
(Fig. 3B), indicating that AsV triggers degradation of this messengers
by the 5′-3′ exonuclease Xrn1 pathway. Because oxidative stress has
been associated with changes in the mRNA stability of the Aft1
regulon [21], and because As compounds induce oxidative stress,
we also analyzed FET3 expression in the presence of H2O2. As
shown in Fig. 3C we did not observe any decrease of the FET3
mRNA upon addition of H2O2, suggesting that AsV-mediated FET3
degradation is independent of ROS formation. Taken together,
these results demonstrate that As triggers FET3mRNA degradation
by Xrn1.
Fig. 2. Aft1 activation in response to arsenate stress. (A) Time-course representation of AFT1-GFP fusion expressed diffusely throughout the cytoplasm while in presence of arsenate
(AsV) after 40 minutes localizes to the nucleus. (B) Nuclear fractionation of wild-type cells expressing Aft1-Myc. In presence of arsenate (AsV) Aft1 is mainly found in the nuclear
fraction. Cytosolic fraction was identiﬁed by incubation with an antibody against Pgk1. (C) Arsenate (AsV) induces the expression of CTH2-lacZ reporter construct. (D) aft1mutant is
sensitive to arsenate (AsV) and recovers upon supplementation with iron (Fe3+).
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Fig. 3. Exonuclease Xrn1 mediates FET3 mRNA degradation upon arsenate addition. (A) FET3 mRNA down-regulation is Cth2 independent. (B) Upon arsenate (AsV) addition FET3
expression levels remain stable only in the absence of XRN1. (C) FET3 mRNA degradation is independent of the ROS formation.
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levels and plasma membrane expression
To explore the consequences of the decrease of FET3mRNA levels,
we ﬁrst checked Fet3 protein levels. AsV caused a decrease in these
levels that started 4 hours after drug exposure; for comparison, the
decrease and increase in Fet3 levels observed under Fe repletion
(Fe3+) and depletion (BPS) are shown (Fig. 4A). Felice et al. reported
that high Fe levels cause not only the repression of the Aft1 Fe
regulon, but also the internalization and degradation of the Fet3/
Ftr1 transport system [6]. Thus as another way of checking Fet3 ex-
pression, we examined its cellular localization (Fig. 4B). In untreated
cells and in cells treated with copper, Fet3 was largely localized at the
plasma membrane. However, after 5 minutes exposure to AsV, Fet3
was essentially detected in an internal compartment resembling the
endoplasmic reticulum (ER), as indicated by the localization of the
ER marker SEC63. As expected, Fet3 was similarly localized in
copper-depleted cells (BCS) [22]. After 60 minutes exposure to AsV,
Fet3 was still in the ER. To evaluate the functional consequence of
these changes in Fet3p expression, we examined the effect of AsV
on the Fe total cellular content. A 4 hours treatment with AsV at
1 mM caused a 70% decrease on the Fe cellular content (Fig. 4C). To
evaluate whether the decrease in Fe was due to impairment of the
Fet3–Ftr1 Fe reductive pathway, we checked whether addition of var-
ious siderophores to the medium could restore the cellular Fe content
of AsV-treated cells by recruitment of the non-reductive pathway of
the Arn proteins family. Addition of a cocktail of siderophores indeed
fully restored the Fe cellular content of AsV-treated cells, and this ef-
fect was dependent upon the presence of Aft1 (Fig. 4C).
By decreasing Fet3 expression, AsV thus causes defective high afﬁn-
ity Fe uptake and eventually Fe deﬁciency. Further AsV toxicity appears,
at least in part, due to Fe deﬁciency, as suggest the improvement of AsV
tolerance by exogenous Fe3+ (see Fig. 2D). We checked whether
AsV-induced Aft1 activation was also the consequence of AsV-induced
Fe deﬁciency. To this end, we compared the time-dependent expression
of CTH2 and FET3 during 1 hour after As exposure (Fig. 4D). Interesting-
ly, FET3 mRNA levels started to decrease 10 minutes after drug expo-
sure and became undetectable at 1 hour, whereas CTH2 mRNA levels
started to increase at 50 min, long after FET3 mrRNA disappearance.
These data indicate that AsV-induced Aft1 activation is a consequence
of AsV-induced defective high-afﬁnity Fe uptake and Fe deﬁciency.
3.5. The Fet3–Ftr1 high afﬁnity Fe uptake system contributes to arsenate
cellular uptake
To test the possible relevance of Fet3 in mediating As biological ef-
fects, we assayed the As tolerance of the fet3ftr1 double mutant.Surprisingly, this mutant was signiﬁcantly more resistant to AsV
than its WT counterpart, indicating that Fet3 and Ftr1 are required
to mediate As toxicity. In keeping with this idea, the xrn1 mutation
that prevents AsV-induced FET3 mRNA degradation and hence Fet3
levels down-modulation, is more sensitive to AsV than the WT strain
(Fig. 5A). fet3ftr1 was also strongly protected from AsV-induced
growth inhibition in liquid medium and from AsV-induced cell
death (~20% vs. 90 % at 1 mM AsV), (Fig. 5B and C). To understand
the basis of the As resistance of the fet3ftr1mutant, we comparatively
measured the As content in these and in wild-type cells treated with
1 mM of AsV for 2 hours. Fig. 5D shows that As levels in the fet3ftr1
mutant were only 30% of those measured in wild-type cells. These re-
sults strongly suggest that the Fet3–Ftr1 high afﬁnity Fe uptake sys-
tem contributes to AsV cellular uptake.
3.6. Arsenic trioxide destabilizes Fe uptake in mammalian cells
Arsenic trioxide (AsIII) is a small molecule used in the treatment of
PML. Although this compoundwas shown to cause damage to/or degra-
dation of the PML protein/retinoic acid receptor-alpha (PML/RARα) fu-
sion protein, thereby inducing apoptosis of acute PML cells [23], its
mechanism of action is not fully understood. To extend the results
obtained in yeast, we checked whether AsIII could also perturb Fe up-
take in mammalian cells, using mouse embryo ﬁbroblasts (MEFs) and
HeLa cells. In mammals, ferritin synthesis is post-transcriptionally reg-
ulated by the Iron Regulatory Protein (IRP) cytosolic Fe availability. In
Fe deplete cells, IRP binds the ferritin mRNA 5′ Iron Response Element
(IRE) preventing translation, whereas in Fe replete cells IRP no longer
binds the 5′ ferritin mRNA IRE, thereby allowing translation, [24]. As
shown in Fig. 6 expression of ferritin was indeed reduced under low
Fe conditions, and increased in the presence of Fe3+. Interestingly the
presence of AsIII signiﬁcantly prevented the Fe3+-induced increase in
ferritin protein levels. Moreover, this effect of AsIII was speciﬁc for Fe
since levels of the copper chaperone for superoxide dismutase Ccs1,
which are inversely correlated with the intracellular copper (Cu) con-
centration [25], were unaffected by AsIII. This result indicates that as
in yeast, As interferes with Fe metabolism, possibly by preventing Fe
uptake.
4. Discussion
Several mechanisms have been proposed to explain As toxicity and
carcinogenicity [26] however, a link between As and Fe homeostasis
has so far never been described. We provide here evidence that in the
single-celled eukaryote S. cerevisiae, the high afﬁnity Fe uptake system
Fet3–Ftr1 is a major determinant of As toxicity by contributing to AsV
cellular uptake. We also show that yeast cells respond to AsV by
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Fig. 5. fet3ftr1mutant is tolerant to arsenate exposure. (A) Sensitivity of fet3ftr1, xrn1mutants and the respective wild-type cells to 1 mM AsV. (B) and (C) Arsenic cell survival and
growth curves, respectively. Data are expressed as percentages of colonies formed compared to the control cultures.
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scripts, thereby preventing AsV uptake, at the price of becoming Fe
deﬁcient.
While analyzing the S. cerevisiae genome-wide response to AsV by
DNA microarrays, we observed that the genes of the Fe regulon consti-
tute an important component of the AsV genomic response, but para-
doxically the FET3 and FTR1 transcripts were very low in AsV-treated
cells (Fig. 1C). As the transcription factor Aft1, which in response to Fe
deprivation induces expression ofmany genes of the Fe regulon, includ-
ing FET3 and FTR1, is potently activated in AsV-treated cells (Fig. 2), we
searched for a post-transcriptional regulatory mechanism that could
explain the decrease of the later transcripts. We found that in AsV-
treated cells the FET3 and FTR1 transcripts were degraded by the 5′-3′
exonuclease Xrn1 (Fig. 3B), thereby causing a signiﬁcant decrease inFig. 4. Arsenate exposure reduces Fet3 protein levels and causes mislocalization at the endo
ment. (B) Representation of FET3-GFP strain expressed diffusely throughout the plasmamem
ER. SEC63-GFP was used as a ER-marker and addition of Bathocuproine disulphonate (BSC)
(AsV) exposure yeast cells redirect Fe internalization through the non-reductive transport
upon exposure of arsenate (AsV) 1 mM and addition of siderophores 5 μM (ferrichrome,
100 in untreated conditions. Bars represent the average plus standard deviation of three in
of arsenate (AsV) 2 mM by RT-PCR. The assay was made using biological and technical tripthe levels of the proteins that they encode (Fig. 4A). We also observed
that a GFP-Fet3 fusion protein, which was mainly seen at the plasma
membrane in untreated cells, appeared predominantly at the ER in
AsV-treated cells (Fig. 4B), further indicating a decrease in Fet3 cellular
activity. Fet3, that oxidizes Fe2+ to Fe3+ and Ftr1, constitute the yeast
high afﬁnity Fe uptake system. Decrease in the activity of either or
both proteins should therefore cause Fe deﬁciency, which is what we
observed in AsV-treated cells, based on the decrease of total cellular
Fe, on the lower AsV tolerance of cells lacking Aft1, and on the signiﬁ-
cant improvement of AsV tolerance by exogenous Fe3+ in both wild
type and aft1 cells (Fig. 2D). Additional proof that the observed cellular
Fe deﬁciency of AsV-treated cells is the consequence of a defect of the
high afﬁnity Fe uptake systemwas obtained by the correction of this de-
ﬁciency by addition of siderophores,which turn on an alternate yeast Feplasmic reticulum (ER). (A) Fet3 levels decrease after 4 hours of arsenate (AsV) treat-
brane while in presence of arsenate (AsV) 1 mM after 5 minutes localizes mainly to the
100 μM or Copper (Cu2+) 10 μM were used as control conditions. (C) Upon arsenate
system. The intracellular Fe content levels determined by ICP in the wild-type strain
ferrirubin, enterobactin and desferroxamin) for 4 hours. Values are made relative to
dependent experiments. (D) Kinetic study of CTH2 and FET3 expression upon addition
licates.
Fig. 6. Arsenic trioxide destabilizes Fe uptake in mammals. (A) MEF and HeLa cells
were incubated with an Fe chelator, 5 μM desferroxamine (−Fe), 5 μM arsenic trioxide
(AsIII), and 100 μM ferric ammonium citrate (Fe3+). After 24 hours, media were col-
lected and cells were lysed. Ferritin and Ccs1 levels were detected by western blot
using mouse anti-Ferritin and rabbit anti-Ccs1 antibodies. Anti-tubulin was used as
loading control.
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treated cells should therefore result from AsV-induced Fe deﬁciency.
The kinetics of FET3 and CTH2 expression showing that the CTH2 tran-
script started to increase only after the FET3 message had already
been fully repressed support this idea (Fig. 4D).
We also show that yeast cells lacking the Fet3–Ftr1 high afﬁnity Fe
uptake system are much more resistant to AsV than their wild type
counterpart, while those lacking Xrn1, and therefore unable to de-
grade the corresponding transcripts are much sensitive to this chem-
ical (Fig. 5A). These results together with the observation that yeast
cells lacking Fet3–Ftr1 accumulate much lower amounts of As than
wild type cells (Fig. 5D) strongly suggest that additionally to the phos-
phate transporters [27], the Fet3–Ftr1 system also constitute a route
of AsV uptake in S. cerevisiae. We do not yet understand how Fet3–
Ftr1 complex mediates uptake of AsV. It has been however shown
that Fe in its different chemical forms has strong afﬁnity towards inor-
ganic arsenic ions [28]. Hence a possible explanation is that Fet3–Ftr1
might serve as a channel to uptake arsenate bound to iron. To further
explore this hypothesis a structural study will be required.
In summary, our study has uncovered a surprisingly adapted yeast
cell response to AsV that prevents As toxicity,wherebyAsV initially trig-
gers the Xrn1-dependent degradation of the FET3 and FTR1 transcripts,
which encode a major route of AsV cellular uptake, thereby preventing
subsequent As uptake. The trade off of such a protective response to As
toxicity is the occurrence of a relative Fe cellular deﬁciency, which in
turn activate the Aft1-dependent Fe regulon as a corrective measure
to the later deﬁciency.Whether such a protective response to As is con-
served in higher eukaryotes is unknown. However, impairment by AsIII
of the Fe3+-induced increase in ferritin protein levels observed mainly
in MEF but with less extent in HeLa cell lines indicate that here also As
interferes with Fe metabolism, possibly by inhibiting Fe cellular uptake
(Fig. 6). A possible explanation for this could be related to the fact thatAsIII has the capacity to co-precipitate with Fe3+ [29], which results
in a less soluble compound, therefore inhibiting Fe uptake. Nevertheless
to further explore these observations it should be used amore appropri-
ated cell model with relevance for acute PML, such as NB4 cell line
(acute PML carrying the t(15;17) translocation) [30].
Further work should address the following unsolved question of
how As triggers the Xrn1-dependent degradation of the FET3 and FTR1
transcripts, whether other important transcripts are targeted by Xrn1
in As-treated cells, and what is the biochemical basis by which the
high afﬁnity Fe uptake Fet3–Ftr1 system operate AsV cellular uptake
mechanism. Finally, although the Fet3 homologue inmammals, Cerulo-
plasmin, participates on the Fe export system by oxidizing Fe2+
transported by Ferroportin to Fe3+, before release into the extracellular
medium making it available for the Transferrin receptors and DMT1
(divalent metal transporter 1) to import back inside the cell [31], it
would be important to address whether As uptake bymammal cells in-
volves, as in yeast, the Fe system.
In conclusion, our data describe a hitherto unknown mechanism of
AsV uptake in yeast whichmight be conserved inmammals and it should
be useful considering that As is not only an important toxic chemical, but
is also used in the treatment of PML and other human diseases.
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